4D Molecular Therapeutics Files 8-K
Ticker: FDMT · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulation-fd
TL;DR
4D Molecular Therapeutics just dropped an 8-K, likely with material news. Stay tuned.
AI Summary
On July 23, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning the company is releasing material non-public information to the public. Specific details regarding the nature of this disclosure, such as financial figures or strategic updates, are not provided in the header information.
Why It Matters
This filing signals that 4D Molecular Therapeutics is making a public disclosure of material information, which could impact investors' understanding of the company's current status or future prospects.
Risk Assessment
Risk Level: medium — An 8-K filing often contains significant corporate events or disclosures that can lead to stock price volatility.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- July 23, 2024 (date) — Date of Report
- Regulation FD Disclosure (disclosure) — Item Information
FAQ
What specific event or information is being disclosed in this 8-K filing?
The provided header information for the 8-K filing indicates a 'Regulation FD Disclosure' but does not specify the exact event or information being disclosed.
When was this 8-K filing submitted to the SEC?
The filing was submitted on July 23, 2024.
What is the primary business of 4D Molecular Therapeutics, Inc.?
4D Molecular Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
Where is 4D Molecular Therapeutics, Inc. headquartered?
The company's principal executive offices are located at 5858 Horton Street #455, Emeryville, California, 94608.
What is the Commission File Number for 4D Molecular Therapeutics, Inc.?
The Commission File Number for 4D Molecular Therapeutics, Inc. is 001-39782.
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 13.8 · Accepted 2024-07-23 06:04:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FDMT Nasdaq Glo
Filing Documents
- d864314d8k.htm (8-K) — 23KB
- 0001193125-24-182544.txt ( ) — 146KB
- fdmt-20240723.xsd (EX-101.SCH) — 3KB
- fdmt-20240723_lab.xml (EX-101.LAB) — 18KB
- fdmt-20240723_pre.xml (EX-101.PRE) — 11KB
- d864314d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: July 23, 2024 By: /s/ Uneek Mehra Uneek Mehra Chief Financial and Business Officer